FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103668367> ?p ?o ?g. }

• W2103668367 endingPage "6077" @default.
• W2103668367 startingPage "6077" @default.
• W2103668367 abstract "We read with great interest the recent article by Chinault and colleagues (1), providing evidence that aminobisphosphonate zoledronic acid (ZOL) does not exert a direct antitumor activity against breast cancer cells in vivo. There is extensive preclinical evidence suggesting that aminobisphosphonates exhibit antitumor effects in addition to their therapeutic activity in preserving bone tissue. The underlying inhibitory mechanisms of aminobisphosphonates against tumor cells are primarily through the blockade of the enzyme farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, which prevents prenylation of signaling proteins (e.g., Rho, Ras, Cdc42), leading to the inhibition of tumor cell adhesion, migration, invasion, and proliferation in vitro (2). Whether aminobisphosphonates exhibit direct and/or indirect antitumor effects in animal models remains a matter of intense discussion. Here, the authors used a bioluminescence-based imaging reporter system that is inducible by prenylation inhibitors, such as aminobisphosphonates, and they showed that the treatment of animals with ZOL fails to induce the reporter in human MDA-MB-231 breast tumor xenografts, indicating that the aminobisphosphonate does not directly target cancer cells in vivo (1). However, we would like to point out an aspect of tumor xenograft experiments not adequately addressed by Chinault and colleagues (1), which deserves a remark.The inhibition of FPPS activity by aminobisphosphonates leads to the intracellular accumulation of IPP/ApppI mevalonate metabolites (2). We recently provided in vivo evidence that ZOL (administered at a dose compatible with clinical dosing regimens) induces accumulation of IPP/ApppI in human breast tumors implanted subcutaneously in animals and that human Vγ9Vδ2 T cells (a subset of human T cells) infiltrate and inhibit growth of these tumors producing high IPP/ApppI levels, but not those expressing low IPP/ApppI levels (3). IPP and ApppI are recognized by human Vγ9Vδ2 T cells as tumor phosphoantigens. Importantly, we showed that estrogen receptor–positive breast tumors (T47D, MCF-7) were more likely to produce IPP/ApppI after ZOL treatment because of a higher cellular uptake of ZOL and a higher activity of the mevalonate pathway compared with estrogen receptor–negative breast tumors (MDA-MB-231, MDA-MB-435; ref. 3). We believe these findings (3) may likely explain results obtained by Chinault and colleagues (1). It would be therefore very interesting to determine whether ZOL induces bioluminescence-based reporter activity in estrogen receptor–positive breast cancer cells in vivo.See the Response, p. 6078P. Clezardin has served on advisory boards for Novartis and Amgen and has received lecture fees and a research grant from Novartis and Amgen. P. Clezardin also has other commercial research support and a honoraria from Speakers Bureau from Novartis and AMGEN." @default.
• W2103668367 created "2016-06-24" @default.
• W2103668367 creator A5045029537 @default.
• W2103668367 date "2012-10-08" @default.
• W2103668367 modified "2023-10-15" @default.
• W2103668367 title "Bioluminescence Imaging of Prenylation Inhibition–Letter" @default.
• W2103668367 cites W2042242992 @default.
• W2103668367 cites W2045031638 @default.
• W2103668367 cites W2149114412 @default.
• W2103668367 cites W2154720522 @default.
• W2103668367 doi "https://doi.org/10.1158/1078-0432.ccr-12-2569" @default.
• W2103668367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23045244" @default.
• W2103668367 hasPublicationYear "2012" @default.
• W2103668367 type Work @default.
• W2103668367 sameAs 2103668367 @default.
• W2103668367 citedByCount "0" @default.
• W2103668367 crossrefType "journal-article" @default.
• W2103668367 hasAuthorship W2103668367A5045029537 @default.
• W2103668367 hasBestOaLocation W21036683671 @default.
• W2103668367 hasConcept C111335760 @default.
• W2103668367 hasConcept C150903083 @default.
• W2103668367 hasConcept C161997846 @default.
• W2103668367 hasConcept C181199279 @default.
• W2103668367 hasConcept C185592680 @default.
• W2103668367 hasConcept C207001950 @default.
• W2103668367 hasConcept C2778827360 @default.
• W2103668367 hasConcept C2779982574 @default.
• W2103668367 hasConcept C502942594 @default.
• W2103668367 hasConcept C54009773 @default.
• W2103668367 hasConcept C54355233 @default.
• W2103668367 hasConcept C553450214 @default.
• W2103668367 hasConcept C55493867 @default.
• W2103668367 hasConcept C57790582 @default.
• W2103668367 hasConcept C71924100 @default.
• W2103668367 hasConcept C81885089 @default.
• W2103668367 hasConcept C86803240 @default.
• W2103668367 hasConcept C98274493 @default.
• W2103668367 hasConceptScore W2103668367C111335760 @default.
• W2103668367 hasConceptScore W2103668367C150903083 @default.
• W2103668367 hasConceptScore W2103668367C161997846 @default.
• W2103668367 hasConceptScore W2103668367C181199279 @default.
• W2103668367 hasConceptScore W2103668367C185592680 @default.
• W2103668367 hasConceptScore W2103668367C207001950 @default.
• W2103668367 hasConceptScore W2103668367C2778827360 @default.
• W2103668367 hasConceptScore W2103668367C2779982574 @default.
• W2103668367 hasConceptScore W2103668367C502942594 @default.
• W2103668367 hasConceptScore W2103668367C54009773 @default.
• W2103668367 hasConceptScore W2103668367C54355233 @default.
• W2103668367 hasConceptScore W2103668367C553450214 @default.
• W2103668367 hasConceptScore W2103668367C55493867 @default.
• W2103668367 hasConceptScore W2103668367C57790582 @default.
• W2103668367 hasConceptScore W2103668367C71924100 @default.
• W2103668367 hasConceptScore W2103668367C81885089 @default.
• W2103668367 hasConceptScore W2103668367C86803240 @default.
• W2103668367 hasConceptScore W2103668367C98274493 @default.
• W2103668367 hasIssue "21" @default.
• W2103668367 hasLocation W21036683671 @default.
• W2103668367 hasLocation W21036683672 @default.
• W2103668367 hasOpenAccess W2103668367 @default.
• W2103668367 hasPrimaryLocation W21036683671 @default.
• W2103668367 hasRelatedWork W2000557393 @default.
• W2103668367 hasRelatedWork W2061731602 @default.
• W2103668367 hasRelatedWork W2093164779 @default.
• W2103668367 hasRelatedWork W2586402484 @default.
• W2103668367 hasRelatedWork W2779447660 @default.
• W2103668367 hasRelatedWork W2917806359 @default.
• W2103668367 hasRelatedWork W2946004068 @default.
• W2103668367 hasRelatedWork W3127211774 @default.
• W2103668367 hasRelatedWork W3156774255 @default.
• W2103668367 hasRelatedWork W3173410576 @default.
• W2103668367 hasVolume "18" @default.
• W2103668367 isParatext "false" @default.
• W2103668367 isRetracted "false" @default.
• W2103668367 magId "2103668367" @default.
• W2103668367 workType "article" @default.